# Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas

> **NCT05937776** · — · RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 20 (estimated)

## Conditions studied

- Glioma

## Interventions

- **OTHER:** Fludeoxyglucose F-18
- **OTHER:** Gadoterate Meglumine
- **PROCEDURE:** Contrast-enhanced Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05937776
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-11
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05937776

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05937776, "Developing a New Metabolic Imaging Approach (aMRI) for Evaluating Neurological Disease in Patients With Gliomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05937776. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*